952479-66-2

Basic information

• Product Name: methyl 2-{4-[(dimethylamino)methyl]-phenyl}-2H-indazole-7-carboxylate
• Synonyms: methyl 2-{4-[(dimethylamino)methyl]-phenyl}-2H-indazole-7-carboxylate
• CAS NO: 952479-66-2
• Molecular Weight: 309.368
• Mol File: 952479-66-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 2-{4-[(dimethylamino)methyl]-phenyl}-2H-indazole-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-{4-[(dimethylamino)methyl]-phenyl}-2H-indazole-7-carboxylate(952479-66-2)
• EPA Substance Registry System: methyl 2-{4-[(dimethylamino)methyl]-phenyl}-2H-indazole-7-carboxylate(952479-66-2)

Safety Data

• Hazardous Substances Data: 952479-66-2(Hazardous Substances Data)

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 755752-82-0 methyl 2H-indazole-7-carboxylate 
• 952479-64-0 methyl 2-(4-formylphenyl)-2H-indazole-7-carboxylate 
• 124-40-3 dimethyl amine 

Relevant articles and documents

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

We disclose the development of a novel series of 2-phenyl-2H-indazole-7- carboxamides as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.